<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647554</url>
  </required_header>
  <id_info>
    <org_study_id>UTI-S001</org_study_id>
    <nct_id>NCT02647554</nct_id>
  </id_info>
  <brief_title>Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China</brief_title>
  <official_title>A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Techpool Bio-Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of
      Ulinastatin Treatment in Adult Patients with Sepsis and Septic Shock in China
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigational drug：Ulinastain for Injection

      Study title： A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial
      of Ulinastatin Treatment in Adult Patients with Sepsis and Septic Shock in China

      Principal Investigator：Professor Bin Du, Medical Intensive Care Unit, Peking Union Medical
      College Hospital; Professor Xiangyou Yu, Critical Care Medicine, First Affiliated Hospital,
      Xinjiang Medical University

      Study subjects： Adult patients with sepsis and septic shock will be eligible for inclusion if
      all of the inclusion criteria are met within 48 hours of meeting criteria of sepsis-3
      definition

      Study phase： Investigator Initiated Trial(IIT)

      Study objectives： The primary objective of the study is to determine whether ulinastatin,
      compared to placebo, reduces 28-day all-cause mortality in patients with sepsis and septic
      shock

      Study design： Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled,
      Clinical Trial

      Medication method：

        -  Ulinastain treatment group： 400,000 IU ulinastatin or matching placebo will be
           reconstituted in 10 mL of 0.9% normal saline, and then dissolved in 100 mL of 0.9%
           normal saline every 8 hours for 10 days in a double-blind fashion. Intravenous infusion,
           The study drug will be infused intravenously over 1 hour.

        -  Placebo control group：Matching with medication

      Course：10 days

      Sample size： 348(174 patients of treatment group, 174 patients of control group)

      Sites： 15

      Primary endpoint：The primary outcome measure for the study is death from all causes at
      28-days.

      Secondary endpoints:

        -  Mortality rate at 90-days

        -  Mortality rate in ICU

        -  Mortality rate at hospital discharge

        -  ICU-free days in 28 days

        -  Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score at 1, 3,
           6, 10,14, and 28 days after randomization

        -  Incidence and duration of supportive care for organ dysfunction including vasoactive
           agents, invasive or noninvasive mechanical ventilation, continuous renal replacement
           therapy(CRRT)

        -  Blood lactate concentration at 1, 3, 6 and 10 days after randomization

        -  Condition of fluid balance within 10 days after randomization

        -  High-sensitivity C-reactive protein (hs-CRP), IL-6, IL-10, TNF-α at 1, 3,6 and 10 days
           after randomization

        -  ADL level at hospital discharge

      Safety endpoints

        -  adverse events

        -  serious adverse events

        -  vital signs, complete blood counts, chemistry, electrocardiograms
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>28 days</time_frame>
    <description>death from all causes at 28-days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>90 days</time_frame>
    <description>mortality rate at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality in ICU</measure>
    <time_frame>through ICU discharge, an average of 14 days</time_frame>
    <description>mortality rate at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate at hospital discharge</measure>
    <time_frame>through hospital discharge, an average of 21 days</time_frame>
    <description>mortality rate at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>28 days</time_frame>
    <description>The time not indwelling in ICU in 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 1,3,6,10,14,28 after randomization</time_frame>
    <description>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score at 1, 3, 6, 10,14, and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of supportive care</measure>
    <time_frame>through ICU discharge, an average of 14 days</time_frame>
    <description>Incidence of supportive care for organ dysfunction including vasoactive agents, invasive or noninvasive mechanical ventilation, continuous renal replacement therapy(CRRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of supportive care</measure>
    <time_frame>through ICU discharge, an average of 14 days</time_frame>
    <description>Duration of supportive care for organ dysfunction including vasoactive agents, invasive or noninvasive mechanical ventilation, continuous renal replacement therapy(CRRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lactate concentration</measure>
    <time_frame>Day 1,3,6,10 after randomization</time_frame>
    <description>Blood lactate concentration at 1, 3, 6 and 10 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluid balance</measure>
    <time_frame>through ICU discharge, an average of 10 days</time_frame>
    <description>Condition of fluid balance in ICU after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum hsCRP</measure>
    <time_frame>Day 1,3,6,10 after randomization</time_frame>
    <description>High-sensitivity C-reactive protein (hs-CRP) at 1, 3,6 and 10 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum IL-6</measure>
    <time_frame>Day 1,3,6,10 after randomization</time_frame>
    <description>IL-6 at 1, 3,6 and 10 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum IL-10</measure>
    <time_frame>Day 1,3,6,10 after randomization</time_frame>
    <description>IL-10 at 1, 3,6 and 10 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum TNF-α</measure>
    <time_frame>Day 1,3,6,10 after randomization</time_frame>
    <description>TNF-α at 1, 3,6 and 10 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete blood counts</measure>
    <time_frame>Day 1-10, 14, 28 after randomization</time_frame>
    <description>Complete blood counts at 1-10, 14, 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function (alanine aminotransferase, ALT)</measure>
    <time_frame>Day 1-10, 14, 28 after randomization</time_frame>
    <description>Hepatic (ALT) function tests at 1-10,14 and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function (Aspartate transaminase, AST)</measure>
    <time_frame>Day 1-10, 14, 28 after randomization</time_frame>
    <description>Hepatic (AST) function tests at 1-10,14 and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function (bilirubin)</measure>
    <time_frame>Day 1-10, 14, 28 after randomization</time_frame>
    <description>Hepatic (bilirubin) function tests at 1-10,14 and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory function</measure>
    <time_frame>Day 1-10, 14, 28 after randomization</time_frame>
    <description>respiratory(PaO2/FiO2) function tests at 1-10,14 and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>Day 1-10, 14, 28 after randomization</time_frame>
    <description>renal (creatinine) function tests at 1-10,14 and 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living (ADL) at hospital discharge</measure>
    <time_frame>through hospital discharge, an average of 21 days</time_frame>
    <description>Activities of daily living (ADL) level at hospital discharge. This scale is used to assess the patient's ability to run a daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>till 28 days after randomization</time_frame>
    <description>incidence, duration and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse events</measure>
    <time_frame>till 28 days after randomization</time_frame>
    <description>incidence, duration and severity of serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Ulinastatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulinastain treatment group：400,000 IU ulinastatin will be reconstituted in 10 mL of 0.9% normal saline, and then dissolved in 100 mL of 0.9% normal saline every 8 hours for 10 days in a double-blind fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control group：Matching with medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ulinastatin</intervention_name>
    <description>ulinastatin 400,000 IU every 8 hours for 10 days</description>
    <arm_group_label>Ulinastatin group</arm_group_label>
    <other_name>urinary trypsin inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo every 8 hours for 10 days</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients will be eligible for inclusion if all of the inclusion criteria
        are met

        1) Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of
        Intensive Care Medicine(ESICM)

          1. Suspected or confirmed infection AND

          2. Evidence of acute organ dysfunction • in patients not known to have preexisting organ
             dysfunction (The baseline SOFA score can be assumed to be zero): total SOFA score ≥2
             points from 48 hours before infection to 24 hours after infection.

             • in patients known to have preexisting organ dysfunction (The baseline SOFA score can
             be assumed according to baseline conditions): changes of total SOFA score ≥2 points
             from 48 hours before infection to 24 hours after infection.

             2）48 hours within diagnosis of sepsis 3）Signed and dated informed consent should be
             obtained prior to any screening procedures from subjects (or legal representatives).
             If the subject is unable to provide consent, it could be obtained from legal
             representatives according to local regulation. Consent from subject should be obtained
             afterwards when available.

             4） Fertile men or women should agree to use efficient birth control methods during the
             treatment period and at least 28 days after last dose. Fertile is defined as
             biologically fertile and sexually active from investigator's view.

             5） Non-childbearing women (meet at least one of following criteria):

             • Past hysterectomy or bilateral oothectomy；

             • Medically confirmed ovarian failure, or menopause (amenorrhea for 12 month or more
             and with no other pathological or physiological reason)

             Exclusion Criteria:

             1) Age &lt; 18 years, or age&gt;80 years 2) Pregnancy or lactating 3) New York Heart
             Association Class IV congestive heart failure, nonseptic cardiogenic shock, or
             uncontrolled acute blood loss 4) Severe, preexisting, parenchymal liver disease with
             clinically significant portal hypertension, Child-Pugh C stage cirrhosis or acute
             liver failure 5) Receipt of a solid-organ or bone marrow transplant 6) Advanced
             pulmonary fibrosis or non invasive ventilation before study entry 7) Myocardial
             infarction within the previous 3 months 8) Cardiopulmonary resuscitation within 72
             hours before study entry 9） Invasive fungal infection or active pulmonary tuberculosis
             10) Full-thickness thermal or chemical burn involving 30% or more of body surface area
             11) Evidence of significant drug- or disease-induced immunosuppression

             · Evidence of moderate or severe neutropenia, i.e. absolute neutrophil count (ANC) &lt;
             1.0 x 10^9/L

               -  Administration of high doses of corticosteroids, i.e. doses of &gt; 20 mg/day of
                  prednisone or equivalent, for ≥ 2 weeks immediately prior to evaluation for
                  enrollment. Hydrocortisone at dose ≤ 300 mg/d for treatment of septic shock is
                  acceptable.

               -  Immunomodulatory medication (e.g. cyclosporine, azathioprine, OKT3),
                  chemotherapy, or radiation therapy within 2 months before study entry

               -  Known HIV seropositivity

               -  Any disease sufficiently advanced to suppress resistance to infection

               -  Non-remission stage of hematological/lymphoid tumor 12) Previous Xuebijing,
                  thymosin or IVIG Within 2 months before study entry 12) Inability to obtain
                  informed consent or assent 13) Participation in an investigational clinical trial
                  within 6 months of screening 14) Expected survival &lt; 2 months or chronic
                  vegetative state 15) Lack of commitment to full, aggressive, life support 16)
                  History of hypersensitivity to ulinastatin or any excipients or preservatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Du, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bin Du, MD</last_name>
    <phone>0086-10-69155036</phone>
    <email>dubin98@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Jiang, MD</last_name>
    <phone>0086-10-69154035</phone>
    <email>edwardjw@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Du, MD</last_name>
      <phone>0086-10-69155036</phone>
      <email>dubin98@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chalfin DB, Holbein ME, Fein AM, Carlon GC. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA. 1993 Jan 13;269(2):249-54.</citation>
    <PMID>8417245</PMID>
  </reference>
  <reference>
    <citation>Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10.</citation>
    <PMID>11445675</PMID>
  </reference>
  <reference>
    <citation>Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004 Apr;30(4):589-96. Epub 2004 Feb 12. Erratum in: Intensive Care Med. 2004 Jun;30(6):1252.</citation>
    <PMID>14963646</PMID>
  </reference>
  <reference>
    <citation>Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003 Sep;31(9):2332-8.</citation>
    <PMID>14501964</PMID>
  </reference>
  <reference>
    <citation>Brun-Buisson C, Meshaka P, Pinton P, Vallet B; EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004 Apr;30(4):580-8. Epub 2004 Mar 2.</citation>
    <PMID>14997295</PMID>
  </reference>
  <reference>
    <citation>Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, Fang Q, Xu Q, Wang D, Jin Y, Yuan S, Wang J, Du Z, Sun Y, Fang X. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med. 2007 Nov;35(11):2538-46.</citation>
    <PMID>17828034</PMID>
  </reference>
  <reference>
    <citation>Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013 Nov 21;369(21):2063. doi: 10.1056/NEJMc1312359.</citation>
    <PMID>24256390</PMID>
  </reference>
  <reference>
    <citation>Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 Feb;39(2):165-228. doi: 10.1007/s00134-012-2769-8. Epub 2013 Jan 30.</citation>
    <PMID>23361625</PMID>
  </reference>
  <reference>
    <citation>Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther. 2011 Nov;9(11):1013-33. doi: 10.1586/eri.11.122. Review.</citation>
    <PMID>22029521</PMID>
  </reference>
  <reference>
    <citation>Sharony R, Yu PJ, Park J, Galloway AC, Mignatti P, Pintucci G. Protein targets of inflammatory serine proteases and cardiovascular disease. J Inflamm (Lond). 2010 Aug 30;7:45. doi: 10.1186/1476-9255-7-45.</citation>
    <PMID>20804552</PMID>
  </reference>
  <reference>
    <citation>Inoue K, Takano H, Yanagisawa R, Yoshikawa T. Protective effects of urinary trypsin inhibitor on systemic inflammatory response induced by lipopolysaccharide. J Clin Biochem Nutr. 2008 Nov;43(3):139-42. doi: 10.3164/jcbn.2008059. Epub 2008 Oct 31.</citation>
    <PMID>19015747</PMID>
  </reference>
  <reference>
    <citation>Huang N, Wang F, Wang Y, Hou J, Li J, Deng X. Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res. 2013 Jun 15;182(2):296-302. doi: 10.1016/j.jss.2012.10.043. Epub 2012 Nov 9.</citation>
    <PMID>23158408</PMID>
  </reference>
  <reference>
    <citation>Shao YM, Zhang LQ, Deng LH, Yao HG. [Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2005 Apr;17(4):228-30. Chinese.</citation>
    <PMID>15836828</PMID>
  </reference>
  <reference>
    <citation>Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, Iyer S. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8. doi: 10.1007/s00134-014-3278-8. Epub 2014 Apr 16.</citation>
    <PMID>24737258</PMID>
  </reference>
  <reference>
    <citation>Yuhara H, Ogawa M, Kawaguchi Y, Igarashi M, Shimosegawa T, Mine T. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis. J Gastroenterol. 2014 Mar;49(3):388-99. doi: 10.1007/s00535-013-0834-x. Epub 2013 May 30. Review.</citation>
    <PMID>23720090</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>December 11, 2016</last_update_submitted>
  <last_update_submitted_qc>December 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Bin Du</investigator_full_name>
    <investigator_title>Director of Medical ICU</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>Ulinastatin</keyword>
  <keyword>adult</keyword>
  <keyword>China</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinastatin</mesh_term>
    <mesh_term>Trypsin Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://pan.baidu.com/s/1eQJUJDK</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

